Insider Transaction Report - Amicus Therapeutics, Inc.

This filing details insider transactions for Amicus Therapeutics, Inc. (FOLD) on April 27, 2026. Director Roberts Eiry disposed of 76,275 shares of Common Stock at $14.50 per share. Additionally, several stock options were cancelled and converted into cash payments following the acquisition of the Issuer by BioMarin Pharmaceutical Inc. These options, including amounts of 40,625, 45,423, 30,474, 42,467, and 74,872 shares of Common Stock, were fully vested and their cancellation was part of the merger. The transaction codes indicate disposal, and post-transaction holdings for these securities are reported as zero.